Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Association of Reduced Immunohistochemical Expression of E-cadherin with a Poor Ovarian Cancer Prognosis - Results of a Meta-analysis

  • Peng, Hong-Ling (Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University) ;
  • He, Lei (Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University) ;
  • Zhao, Xia (Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University)
  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: E-cadherin is a transmemberane protein which is responsible for adhesion of endothelial cells. The aim of our study was to assess existing evidence of associations between reduced expression of E-cadherin and prognosis of ovarian cancer with a discussion of potential approaches to exploiting any prognostic value for improved clinical management. Methods: We conducted a meta-analysis of 9 studies (n=915 patients) focusing on the correlation of reduced expression of E-cadherin with overall survival. Data were synthesized with random or fixed effect hazard ratios. Results: The studies were categorized by author/year, number of patients, FIGO stage, histology, cutoff value for E-cadherin positivity, and methods of hazard rations (HR) estimation, HR and its 95% confidence interval (CI). Combined hazard ratios suggested that reduced expression of E-cadherin positivity was associated with poor overall survival (OS), HR= 2.10, 95% CI:1.13-3.06. Conclusion: The overall survival of the E-cadherin negative group with ovarian cancer was significant poorer than the E-cadherin positive group. Upregulation of E-cadherin is an attractive therapeutic approach that could exert significant effects on clinical outcome of ovarian cancer.

Keywords

References

  1. Altundag K, Altundag O, Akyurek S, et al (2006). Inactivation of E-cadherin and less sensitivity of lobular breast carcinoma cells to chemotherapy. Breast, 15, 300. https://doi.org/10.1016/j.breast.2005.10.007
  2. Barraclough H, Simms L, Govindan R (2011). Biostatistics primer: what a clinician ought to know: hazard ratios. J Thorac Oncol, 6, 978-2. https://doi.org/10.1097/JTO.0b013e31821b10ab
  3. Berx G, van Roy F (2009). Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol, 1, a003129. https://doi.org/10.1101/cshperspect.a003129
  4. Blechschmidt K, Sassen S, Schmalfeldt B, et al (2008). The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer, 98, 489-5. https://doi.org/10.1038/sj.bjc.6604115
  5. Carter JS, Downs LS Jr (2011). Ovarian cancer test and treatment. Female Patient (Parsippany). 36, 30-5.
  6. Cho EY, Choi Y, Chae SW, et al (2006). Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int, 56, 62-0. https://doi.org/10.1111/j.1440-1827.2006.01925.x
  7. Cisco RM, Ford JM, Norton JA (2008). Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery. Cancer, 113, 1850-6. https://doi.org/10.1002/cncr.23650
  8. Darai E, Scoazec JY, Walker-Combrouze F, et al (1997). Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum Pathol, 28, 922-8. https://doi.org/10.1016/S0046-8177(97)90007-1
  9. Dian D, Brüning A, Mylonas I (2011). E-cadherin as a prognostic marker in human serous carcinomas of the ovary: an immunohistochemical analysis. Arch Gynecol Obstet, 284, 437-3. https://doi.org/10.1007/s00404-010-1657-0
  10. Engelman JA (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer, 9, 550-62. https://doi.org/10.1038/nrc2664
  11. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, et al (2004). Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Onco, 15, 1535-2. https://doi.org/10.1093/annonc/mdh387
  12. Fluge O, Bruland O, Akslen LA, et al (2006). Gene expression in poorly differentiated papillary thyroid carcinomas. Thyroid, 16, 161-5. https://doi.org/10.1089/thy.2006.16.161
  13. Gadducci A, Ferdeghini M, Cosio S, et al (1999). Preoperative serum E-cadherin assay in patients with ovarian carcinoma. Anticancer Res, 19, 769-2.
  14. Haslehurst AM, Koti M, Dharsee M, et al (2012). EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer, 12, 91. https://doi.org/10.1186/1471-2407-12-91
  15. Hirohashi S, Kanai Y (2003). Cell adhesion system and human cancer morphogenesis. Cancer Sci, 94, 575-1. https://doi.org/10.1111/j.1349-7006.2003.tb01485.x
  16. Ho CM, Cheng WF, Lin MC, et al (2010). Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma. Int J Gynecol Cancer, 20, 1490-7.
  17. Huang KJ, Sui LH (2012). The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2 and E-cadherin in epithelial ovarian cancer. Med Oncol, 29, 318-3. https://doi.org/10.1007/s12032-010-9817-4
  18. Janda E, Nevolo M, Lehmann K, et al (2006). Raf plus TGF betadependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin. Oncogene, 25, 7117-30. https://doi.org/10.1038/sj.onc.1209701
  19. Lau MT, Klausen C, Leung PC (2011). E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via $\beta$-catenin-Egr1-mediated PTEN expression. Oncogene, 30, 2753-66. https://doi.org/10.1038/onc.2011.6
  20. Mareel M, Berx G, Van Roy F, et al (1996). Cadherin/catenin complex: a target for antiinvasive therapy? J Cell Biochem, 61, 524-0. https://doi.org/10.1002/(SICI)1097-4644(19960616)61:4<524::AID-JCB5>3.0.CO;2-Q
  21. Martin B, Paesmans M, Mascaux C (2004).Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer, 91, 2018-5. https://doi.org/10.1038/sj.bjc.6602233
  22. Oza AM, Castonguay V, Tsoref D, et al (2011). Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective. Curr Oncol, Suppl 2: S20-7.
  23. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-4. https://doi.org/10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
  24. Perl AK, Wilgenbus P, Dahl U, et al (1998). A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature, 392, 190-3. https://doi.org/10.1038/32433
  25. Polyak K, Weinberg RA (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer, 9, 265-3. https://doi.org/10.1038/nrc2620
  26. Sawada K, Mitra AK, Radjabi AR, et al (2008). Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res, 68, 2329-39. https://doi.org/10.1158/0008-5472.CAN-07-5167
  27. Shim HS, Yoon BS, Cho NH (2009). Prognostic significance of paired epithelial cell adhesion molecule and E-cadherin in ovarian serous carcinoma. Hum Pathol, 40, 693-8. https://doi.org/10.1016/j.humpath.2008.10.013
  28. St Croix B, Sheehan C, Rak JW, et al (1998). E-Cadherindependent growth suppression is mediated by the cyclindependent kinase inhibitor p27(KIP1). J Cell Biol, 142, 557-71. https://doi.org/10.1083/jcb.142.2.557
  29. Vincan E, Barker N (2008). The upstream components of the Wnt signalling pathway in the dynamic EMT and MET associated with colorectal cancer progression. Clin Exp Metastasis, 25, 657-3. https://doi.org/10.1007/s10585-008-9156-4
  30. Voutilainen KA, Anttila MA, Sillanpää SM, et al (2006). Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol, 59, 460-7. https://doi.org/10.1136/jcp.2005.029876
  31. Yamamoto S, Tsuda H, Honda K, et al (2007). Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type. Mod Pathol, 20, 1278-5. https://doi.org/10.1038/modpathol.3800966
  32. Yoshida J, Horiuchi A, Kikuchi N, et al (2009). Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1, and Twist, in the development and progression of ovarian carcinoma. Med Mol Morphol, 42, 82-1. https://doi.org/10.1007/s00795-008-0436-5
  33. Yuecheng Y, Hongmei L, Xiaoyan X (2006). Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis, 23, 65-4. https://doi.org/10.1007/s10585-006-9020-3
  34. Yu F, Yao H, Zhu P, et al (2007). Let-7 regulates self-renewal and tumorigenicity of breast cancer cells. Cell, 131, 1109-23. https://doi.org/10.1016/j.cell.2007.10.054

Cited by

  1. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer vol.287, pp.6, 2013, https://doi.org/10.1007/s00404-012-2684-9
  2. Reactive oxygen species promote ovarian cancer progression via the HIF-1α/LOX/E-cadherin pathway vol.32, pp.5, 2014, https://doi.org/10.3892/or.2014.3448
  3. Prognostic role of Twist or Snail in various carcinomas: a systematic review and meta-analysis vol.44, pp.11, 2014, https://doi.org/10.1111/eci.12343
  4. Down-Regulated E-Cadherin Expression Is Associated with Poor Five-Year Overall Survival in Bone and Soft Tissue Sarcoma: Results of a Meta-Analysis vol.10, pp.3, 2015, https://doi.org/10.1371/journal.pone.0121448
  5. Microvessel Density as a Prognostic Factor in Ovarian Cancer: a Systematic Review and Meta-analysis vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.869
  6. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer vol.21, pp.2, 2015, https://doi.org/10.1007/s12253-014-9827-1
  7. The prognostic implication of slug in all tumour patients - a systematic meta-analysis vol.46, pp.5, 2016, https://doi.org/10.1111/eci.12608